Who Can't Take Mounjaro, and Why It Matters

Which conditions make Mounjaro completely off-limits?

The Mounjaro Summary of Product Characteristics (the definitive prescribing document held on the Electronic Medicines Compendium (eMC)) sets out a small number of hard stops. These aren't judgment calls; they're situations where treatment should not begin regardless of how much weight someone needs to lose.

The clearest absolute contraindication is a personal or family history of medullary thyroid carcinoma. Tirzepatide, like other GLP-1 medicines, caused thyroid tumours in rodent studies, and while a direct human link has not been established, the regulatory position is cautious: if MTC or the associated genetic syndrome MEN2 is in your medical history or your close family's, Mounjaro is not appropriate.

Hypersensitivity to tirzepatide or any of the pen's excipients is the other hard stop. Allergic reactions to the medicine itself, though rare, have been reported, and attempting to manage them through dose adjustment is not an option when the allergen is the medicine.

Beyond these, a history of serious pancreatitis raises a significant clinical flag. The MHRA issued a Drug Safety Update in January 2026 noting that acute pancreatitis is a known, though infrequent, serious effect of GLP-1 medicines. Anyone with a prior episode of pancreatitis needs an honest conversation with their prescriber before starting; many clinicians would decline to prescribe.

Severe gastroparesis or significant inflammatory bowel disease also sit in the caution zone, tirzepatide slows gastric emptying further, which can worsen these conditions in ways that are difficult to manage.

Who else should not start Mounjaro without a careful clinical review?

Beyond absolute contraindications, there is a broader group for whom the picture is genuinely more complicated. These are not blanket refusals, but they do require the prescriber to look harder.

People with type 1 diabetes are not within the licensed indication for tirzepatide's weight-management use. The medicine's mechanism affects insulin secretion and sensitivity; without the natural safeguards present in type 2 diabetes physiology, the risk calculus changes meaningfully.

Severe kidney or liver impairment may affect how tirzepatide is tolerated; the SmPC notes limited data in these groups, and the prescriber will assess this individually. Patients on insulin or insulin secretagogues (such as sulphonylureas) face a real hypoglycaemia risk that requires dose adjustment of the other medicine before Mounjaro is introduced, this is manageable, but it needs clinical oversight, not self-management.

Certain medicines may also affect or be affected by tirzepatide's gastric-emptying mechanism. Oral contraceptives are a good example: for the first four weeks of Mounjaro treatment and for four weeks after each dose increase, women taking the pill are advised to add a barrier method, because absorption of oral hormones can be reduced. Drug interactions with Mounjaro are worth reviewing with your prescriber, particularly if your regular medicines have a narrow therapeutic window. It is always worth flagging every medicine you take during the consultation.

Why can't people who are pregnant or trying to conceive take Mounjaro?

Mounjaro is not recommended during pregnancy, while breastfeeding, or if you are actively trying to conceive. This applies at every dose, and it is not a soft caution, the NHS and the licensed prescribing information are both unambiguous on this point, as noted in the NHS tirzepatide medicines page.

There is simply not enough human safety data. Animal studies raised concerns about foetal development at doses comparable to those used therapeutically. Until robust human data exists, the standard clinical position is that the risk cannot be justified.

The practicalities matter too. Mounjaro has a meaningful washout period before conception is considered safe; your prescriber will advise on timing. Women of childbearing age using Mounjaro should be using effective contraception, and as noted above, the pill alone may not be sufficient during the first weeks of treatment or after dose increases. A barrier method adds the necessary cover.

If your circumstances change while you are on treatment (a pregnancy test comes back positive, for example) stop the medicine and contact your GP promptly. This is not a situation to sit on until the next routine check-in.

Does the BMI threshold mean some people can't take Mounjaro even if they want to?

Yes. The licensed indication is specific: adults with a body mass index of 30 or above, or 27 and above alongside at least one weight-related health condition (such as high blood pressure, high cholesterol, obstructive sleep apnoea or type 2 diabetes). People below these thresholds fall outside the licence, and a responsible prescriber will not start treatment. Understanding the BMI criteria for Mounjaro in full (including which conditions count and how the lower thresholds work for some ethnic backgrounds) is worth doing before you apply.

BMI is also not the only consideration even within the eligible range. Age, existing medical conditions, current medicines and a number of other factors all feed into the prescriber's decision, and our guide to who cannot have Mounjaro covers the full range of contraindications and cautions in one place. The full eligibility picture is set out on our page covering who can take Mounjaro and also in the broader weight-loss treatment overview.

One practical note: if you're planning to order around a bank holiday or a break, it's worth checking the consultation cut-off times in advance, same-day clinical review depends on your application arriving while the prescribers are on shift, not just before midnight. Our FAQs cover dispatch and delivery timing. The Mounjaro treatment page also sets out what the process looks like end to end, and Mounjaro pricing is explained transparently there too.

If any of the cautions above apply to you and you are unsure what they mean in practice, the honest answer is to put that question to a prescriber directly. Our clinical team, including our lead prescriber, reviews every consultation personally. Start that conversation through the free consultation.